Talledo, Nenita F.
HRN: 08-53-62 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/14/2023
CO-AMOXICLAV 625MG (TAB)
07/14/2023
07/21/2023
PO
625mg
Q8hrs
BKA
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes